Molecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool. Here, next-generation sequencing (NGS) of blood-derived ctDNA was performed in patients with advanced colorectal cancer (CRC).
INTRODUCTION
Colorectal cancer (CRC) is a heterogeneous disease that develops as a consequence of different combinations of epigenetic and genetic alterations, with significant variability observed in individual patient prognosis and therapy response, perhaps due to molecular heterogeneity.
Advances in the treatment of patients with metastatic CRC have led to an improvement in patient survival partly due to the use of biologic agents targeting the EGFR signaling pathway or tumor angiogenesis (1) (2) (3) (4) (5) .
Additionally, certain biomarkers with prognostic or predictive value have been identified. For example, activating mutations of KRAS and NRAS can predict a lack of response to anti-EGFR therapy. These mutations frequently co-exist with alterations in the phosphoinositide 3-kinase (PI3K)/Akt/mTOR pathway encoding genes (6) . Hyper-mutated CRC tumors have been found to be excellent targets for programmed death 1 (PD-1) inhibitors (7) . Finally, BRAF mutation is a known poor prognostic feature (1, 8, 9) .
Further understanding of underlying genomic alterations in CRC has been made possible by recent improvements in DNA sequencing technology. The Cancer Genome Atlas network conducted a comprehensive genome-wide analysis of somatic mutations in colorectal tumors. The most commonly altered genes were as follows in non-hypermutated CRCs: APC (81%), TP53 (60%), KRAS (43%), and PIK3CA (18%).
BRAF mutations were frequently associated with hyper-mutated CRCs (10) . In addition, understanding of heterogenous genetic makeup of CRC has led to a consensus on molecular subtypes used to classify CRC (11) .
The development of next-generation sequencing (NGS) platforms and their implementation into clinical use allows for rapid clinical-grade genomic analysis to identify actionable genomic alterations, and thus has led to the use of targeted therapies matched to patients' specific alterations (12) (13) (14) (15) . Until recently, genomic sequencing was typically performed on archival tumor tissue. However, acquisition of tumor tissue is not always feasible, and a tissue biopsy at a single time point may not, due to tumor heterogeneity, provide a recent or complete picture of the molecular background of tumor evolution, response, and resistance (16, 17) . One strategy to overcome these challenges is to investigate circulating biomarkers. Circulating tumor DNA (ctDNA) is shed into bloodstream from cancer cells and can be isolated from blood (also known as a "liquid biopsy") (18) (19) (20) . More recently, the technology has rapidly advanced, and evaluating multiple genes by performing NGS on ctDNA has proven useful when applied in the clinic (21) (22) (23) (24) (25) (26) .
Herein, we describe the results of ctDNA testing in 78 patients with CRC whose blood-derived ctDNA was interrogated by a targeted NGS panel.
Type, distribution, and frequency of genomic alterations, potential actionability, concordance with tissue testing, and emerging resistance alterations detected in ctDNA after anti-EGFR-based therapy (including an illustrative case) are described.
MATERIALS AND METHODS

Patients
We investigated genomic alterations and clinic-pathologic data from electronic medical records in 78 consecutive patients with CRC followed at the University of California San Diego (UCSD) Moores Cancer Center, for whom ctDNA testing was performed on their blood samples between December 2014 and November 2016. This was a retrospective analysis of all eligible patients with available data during the time period. A total of 1005 eligible patients with various cancers had ctDNA analysis during this time period.
Next generation sequencing
ctDNA analyses: Digital sequencing was performed by clinical laboratory improvement amendments (CLIA)-licensed and College of American Pathologist (CAP)-accredited laboratory (Guardant Health, Inc., http://www.guardanthealth.com/). ctDNA was extracted from whole blood collected in 10mL Streck tubes, and 5ng-30ng of ctDNA was prepared for sequencing as previously described (23) . The fractional concentration or variant allele fraction for a given somatic mutation is calculated as the fraction of ctDNA harboring that mutation in a background of wild-type ctDNA fragments at the same nucleotide position. Germline alterations are filtered out and not reported. This ctDNA assay has high sensitivity (detects 85%+ of the single nucleotide variants (SNVs) detected in tissue in advanced cancer patients) and specificity (> 99.9999%) (23) .
Throughout the timeframe of this study, the ctDNA assay expanded gene panels from 54 to 73 genes (Supplemental Table 1 ). There were 104 blood samples collected from a total of 78 patients in this study ( (27) . For tissue NGS, we included only characterized alterations in our analyses.
Concordance
We investigated the concordance for the 61 patients who had both tests performed (tissue and blood). Concordance between tissue and blood was calculated using a kappa coefficient. We examined specific concordance rates for the most frequent alterations including TP53, KRAS, APC, PIK3CA, BRAF and MYC, and all the genes examined were present in the tissue and ctDNA panels.
Definition of actionability
An actionable alteration was defined by UCSD Molecular Tumor Board as a genomic alteration that produces a protein product serving as either the direct target or as part of a signaling pathway that could be impacted by drugs. Drug impact could be impact or via differential expression on tumor versus normal cells. Drugs might be available for on-label (Food and Drug Administration (FDA)-approved for CRC) and/or off-label use (FDAapproved for an indication other than CRC) or in experimental clinical trials. Protein products of genes were considered actionable by small molecule inhibitors if the compound impacted the protein at low 50% inhibitory concentrations. Genes that produced proteins that were recognized as the main target of an antibody were also considered actionable. We also utilized OncoKB (28) as an additional source to define actionability.
Statistical Design
The study was performed under an IRB-approved registry type study (PREDICT). PREDICT has both prospective and retrospective components but, in this case, data was gathered retrospectively. This study was performed in accordance with the UCSD Moores Cancer Center Institutional Review Board guidelines for NCT02478931 and for any investigational therapies to which the patients consented.
RESULTS
Patient characteristics
The median age at first blood draw was 52 years (range, 27 to 82 years); 40 patients (51.3%) were men ( Table 2 ).
When alterations were grouped depending on the oncogenic pathways, genes involved in the mitogen-activated protein kinase (MAPK) signaling pathway were altered in 59.0% (46/78) of patients; TP53-associated genes were altered in 53.8% (42/78); tyrosine kinase families were altered in 37.2% (29/78); the Wnt signaling was altered in 33.3% (26/78); the PI3K signaling was altered in 17.9% (14/78); and cell-cycle associated genes were altered in 14.1% (11/78) ( Table 2) .
Among frequently altered genes, APC had the highest median mutant allele ctDNA fraction of 6.6% (range, 0.1-55.5). Most of the other characterized mutations had a median ctDNA fraction of less than 5%.
There was no clear association between the frequencies of gene alterations and the fraction of ctDNA detected in the blood (Figure 1, 
Panel B).
Actionable genomic alterations among patients with CRC
We determined actionability based on our Molecular Tumor Board assessments (Supplemental Table 4 ) and by OncoKB (28). 
Concordance of the ctDNA test with tissue NGS test
Of the 78 patients who had ctDNA test, 61 patients also had a tissue genomic test. The time between biopsy and blood draw ranged from 1 day to 6.6 years, with a median of 5.0 months. We examined concordance for the most frequent alterations. The concordance rates were 70.5% for TP53, 77.0% for KRAS, 62.3% for APC, 80.3% for PIK3CA, 86.9% for BRAF, 83.6% for MYC ( Table 3 ). There was no statistically significant difference in concordance rates in patients for whom the time interval between biopsy and blood draw used for testing was ≤6 months (N = 35) versus those for whom the time interval was >6 months (N=26).
Emerging resistance alterations in ctDNA along with therapeutic intervention
We documented that emerging resistance alterations could be detected in ctDNA from patients treated with anti-EGFR antibodies. There were nine patients treated with anti-EGFR-based therapy who also had tissue NGS prior to or soon after the therapy. Tissue NGS test was performed at various time points (range, 19 days to 26.9 months) before the initiation of anti-EGFR-based therapy; one patient had it performed one month after the initiation of the therapy (#12). Pretreatment ctDNA was also available in two patients, and both showed no detectable alterations (#1, #30) ( Table 4 ).
In total, we observed 31 alterations that were not detected in the tumor and only appeared in the ctDNA after the therapy was initiated. Of these, we found 15 alterations in genes known to be involved in therapeutic resistance to anti-EGFR therapy ( Table 4 , #2, #12, #38, #68). The progression-free survival of these four patients were 4.6 months, 12.4 months, 6.7 months, and 2.5+ months, respectively; three patients (#2, #12, #38) experienced disease progression at the time of blood draw after a prior response/stable disease, and one patient (#68) was assessed as having stable disease at the time of blood draw, but lost to follow up thereafter. KRAS alterations were observed in two patients (#12, #38); one patient had five molecularly distinct KRAS alterations (KRAS G12A, KRAS G12C, KRAS G13D, KRAS Q61H, and KRAS amplification) and the other had KRAS amplification. Two NRAS mutations in one patient (#12) were observed; NRAS Q61H, NRAS Q61K. BRAF G469A mutation was observed in one patient (#12). EGFR S492R mutation was observed in two patients (#12, #68). Additionally, amplifications in ERBB2 (N = 3) (#2, #12, #38) and MET (N = 1) (#68) were observed.
A representative case (#38) with emerging KRAS and ERBB2 alterations upon progression on anti-EGFRbased therapy is presented (Figure 2 ).
DISCUSSION
We investigated genomic alterations in 78 patients with CRC (77, stage IV) using a targeted NGS assay that analyzed blood-derived ctDNA. Of the total, 63 patients (80.8%) had ≥1 detectable alteration(s), which is consistent with previous reports (23) (24) (25) 29 EGFR mutations were detected in three patients (3.8%) (two, S492R
and one, G465R), and BRAF mutations in four patients (5.1%) (three, V600E and one, G469A). Several previous studies have shown that resistant EGFR ectodomain mutations (S492R, G465R) emerge in patients treated with anti-EGFR therapy (34) (35) (36) . In our study, all three patients who harbored EGFR mutations in ctDNA were previously treated with cetuximab-based regimens, and available pretreatment tumor specimens from two patients confirmed that the EGFR S492R mutation was not present before cetuximab treatment ( Recent actionability studies performed on ctDNA in various solid tumor patients reported that 71-81.5% of patients had at least one clinically actionable alteration (24, 25) , which is consistent with our results.
Accumulating evidence suggests that biomarker-based treatment approach may be able to improve clinical outcome (12) (13) (14) (15) . Clinical utility of this approach in genomically-matched patient populations continues to be investigated in large prospective clinical trials.
Lastly, analysis of ctDNA in serially collected plasma samples allowed detection of emerging mutant ctDNA, which can be used to monitor patients for disease progression as well as to find mechanisms of resistance. In our patients treated with anti-EGFR agents, we could detect multiple emerging alterations in genes known to be involved in therapeutic resistance to anti-EGFR therapy -KRAS, NRAS, BRAF, and EGFR mutations, and amplification of KRAS, ERBB2, and MET -consistent with the implication of many of these genes in both primary as well as acquired resistance to anti-EGFR therapy (29, 34-36, 42, 43, 45-49 ) (see illustrative case, Figure 2) . A limitation of our study is that we did not administer therapy that would impact resistant alterations; future studies should address this issue in order to validate the role of these alterations in resistance.
The study has additional limitations. Importantly, understanding the underlying mechanisms for response and resistance cannot be fully elucidated in the clinic and further bench-side investigations are needed.
The median age of patients was 52, which is young for colorectal cancer, and might reflect a selection bias because of the referral pattern to a tertiary care center or because of physician discretion in ordering ctDNA Table 4 for the rationale of possible targeted therapies. 49-year-old woman with metastatic colon cancer. Tissue NGS at diagnosis showed alterations including TP53 and APC ( Table 4 , case ID #38). After progressing on FOLFIRI plus bevacizumab, patient was started on FOLFOX plus cetuximab. Patient initially had response in left adrenal and retroperitoneal lymph node metastases. However, after 6.7 months of therapy, left adrenal node was progressing, thus patient was taken off from therapy. Post-progression ctDNA showed persistent TP53 and APC alterations as well as emerging KRAS and ERBB2 amplifications. Figure 2 . KRAS wild-type colon cancer patient treated with anti-EGFRbased therapy. ctDNA analysis at progression with multiple emerging resistance alterations.
